CEO changes can help companies suffering from bad executive syndrome. The process can lead to positive outcomes, like new drug developments and vaccines, benefiting the company in the long run.
Under Walmsley's leadership, GSK successfully navigated challenges to develop a vaccine against respiratory syncytial virus, surpassing Pfizer's progress, which showcased significant efficacy.
GSK's vaccine against shareholder activism, coinciding with influenza protection, proved successful in the market, outselling Pfizer's offering in the US.
[
add
]
[
|
|
...
]